Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (4), 183-98

Antibiotic Treatment for Helicobacter Pylori: Is the End Coming?


Antibiotic Treatment for Helicobacter Pylori: Is the End Coming?

Su Young Kim et al. World J Gastrointest Pharmacol Ther.


Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori) has been associated with gastro-duodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Antibiotic resistance to clarithromycin and metronidazole is particularly problematic and several approaches have been proposed to overcome this issue, such as complementary probiotic therapy with Lactobacillus. Other studies have identified novel molecules with an anti-H. pylori effect, as well as tailored therapy and nanotechnology as viable alternative eradication strategies. This review discusses current antibiotic therapy for H. pylori infections, limitations of this type of therapy and predicts the availability of newly developed therapies for H. pylori eradication.

Keywords: Antibiotic resistance; Helicobacter pylori; Novel agents; Therapeutic regimens; Treatment.


Figure 1
Figure 1
Worldwide rates of resistance to clarithromycin and metronidazole.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources